1.
|
8 p, 841.5 KB |
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma : A Randomized Phase 2 Study
/
Lindskog, M. (Department of Immunology. Genetics and Pathology. Uppsala University Hospital. Uppsala University) ;
Laurell, Anna (Department of Oncology. Akademiska University Hospital) ;
Kjellman, Anders (Department of Urology. CLINTEC. Karolinska University Hospital. Karolinska Institutet) ;
Melichar, Bohuslav (Department of Urology and Urological Oncology. Wojewodzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego) ;
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau) ;
Zieliński, Henryk (Clinical Urology. Military Institute of Medicine) ;
Villacampa, Felipe (Hospital Universitario 12 de Octubre (Madrid). Servicio de Urología) ;
Bigot, Pierre (Department of Urology. Centre Hospitalier Universitaire d'Angers) ;
Zoltan, Bajory (Szent-Györgyi Albert Klinikai Központ. Szegedi Tudomanyegyetem Altalanos Ovostudomanyi Kar Urologiai Klinika) ;
Parikh, Omi (Rosemere Cancer Centre. Royal Preston Hospital) ;
Vázquez Alba, David (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Jellvert, Åsa (Department of Oncology. Institute of Clinical Sciences. Sahlgrenska Academy. University of Gothenburg) ;
Flaskó, Tibor (Department of Urology. Medical School. University of Debrecen) ;
Gallardo, Eduard (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Ribal Caparrós, María José (Hospital Clínic i Provincial de Barcelona. Servei d'Urologia) ;
Purkalne, Gunta (Oncology Clinic. Pauls Stradins Clinical University Hospital) ;
Suenaert, Peter (Immunicum AB) ;
Karlsson-Parra, Alex (Department of Immunology. Genetics and Pathology. Section of Clinical Immunology. Uppsala University) ;
Ljungberg, Börje (Department of Surgical and Perioperative Sciences. Urology and Andrology. Umeå University) ;
Universitat Autònoma de Barcelona
Background: The prognosis of patients with synchronous metastatic renal cell carcinoma (mRCC) is poor. Whereas single-agent tyrosine kinase inhibition (TKI) is clearly insufficient, the effects can be enhanced by combinations with immune checkpoint inhibitors. [...]
2022 - 10.1016/j.euros.2022.03.012
European Urology Open Science, Vol. 40 (june 2022) , p. 38-45
|
|
2.
|
18 p, 2.5 MB |
Transfection of Vitamin D3-Induced Tolerogenic Dendritic Cells for the Silencing of Potential Tolerogenic Genes. Identification of CSF1R-CSF1 Signaling as a Glycolytic Regulator
/
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
González-Larreategui, Íñigo (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Figa-Martín, Neus (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Barallat, Jaume (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Fondelli, Federico (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Sellés-Rius, Ares (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
The use of autologous tolerogenic dendritic cells (tolDC) has become a promising strategy to re-establish immune tolerance in autoimmune diseases. Among the different strategies available, the use of vitamin D3 for the generation of tolDC (VitD3-tolDC) has been widely tested because of their immune regulatory properties. [...]
2021 - 10.3390/ijms22147363
International journal of molecular sciences, Vol. 22, Num. 14 (July 2021) , art. 7363
|
|
3.
|
33 p, 9.9 MB |
Vitamin D receptor, STAT3, and TET2 cooperate to establish tolerogenesis
/
Català-Moll, Francesc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ferreté Bonastre, Anna G. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Godoy-Tena, Gerard (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Morante-Palacios, Octavio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ciudad, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Barberà, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fondelli, Federico (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Martínez Cáceres, Eva María (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Rodríguez-Ubreva, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Li, Tianlu (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ballestar, Esteban (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
The active form of vitamin D, 1,25-dihydroxyvitamin D3, induces a stable tolerogenic phenotype in dendritic cells (DCs). This process involves the vitamin D receptor (VDR), which translocates to the nucleus, binds its cognate genomic sites, and promotes epigenetic and transcriptional remodeling. [...]
2022 - 10.1016/j.celrep.2021.110244
Cell reports, Vol. 38 Núm. 3 (18 2022) , p. 110244
|
|
4.
|
19 p, 5.0 MB |
Coordinated glucocorticoid receptor and MAFB action induces tolerogenesis and epigenome remodeling in dendritic cells
/
Morante-Palacios, Octavio. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ciudad, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Micheroli, Raphael (University of Zurich) ;
de la Calle-Fabregat, Carlos (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Li, Tianlu (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Barbisan, Gisela (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Houtman, Miranda (University of Zurich) ;
Edalat, Sam G. (University of Zurich) ;
Frank-Bertoncelj, Mojca (University of Zurich) ;
Ospelt, Caroline (University of Zurich) ;
Ballestar, Esteban (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Glucocorticoids (GCs) exert potent anti-inflammatory effects in immune cells through the glucocorticoid receptor (GR). Dendritic cells (DCs), central actors for coordinating immune responses, acquire tolerogenic properties in response to GCs. [...]
2022 - 10.1093/nar/gkab1182
Nucleic acids research, Vol. 50 Núm. 1 (january 2022) , p. 108-126
|
|
5.
|
|
6.
|
|
7.
|
|
8.
|
|
9.
|
14 p, 1.3 MB |
Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4 + Cells Towards a Functional Hyporesponsiveness
/
Navarro-Barriuso, Juan (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Quirant, Bibiana (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Teniente Serra, Aina (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Ramo-Tello, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Martínez-Cáceres, Eva M. (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
The use of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases. Among the different strategies available, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most robust approaches due to their immune regulatory properties, which are currently being tested in clinical trials. [...]
2021 - 10.3389/fimmu.2020.599623
Frontiers in immunology, Vol. 11 (january 2021)
|
|
10.
|
11 p, 2.0 MB |
Ethyl Pyruvate Induces Tolerogenic Dendritic Cells
/
Djedovic, Neda (University of Belgrade. Department of Immunology) ;
Mansilla Lopez, Maria Jose (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Jevtić, Bojan (University of Belgrade. Department of Immunology) ;
Navarro-Barriuso, Juan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Saksida, Tamara (University of Belgrade. Department of Immunology) ;
Martínez-Cáceres, Eva M. (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Miljković, Ðorđe (University of Belgrade. Department of Immunology)
Dendritic cells (DC) are professional antigen presenting cells that have a key role in shaping the immune response. Tolerogenic DC (tolDC) have immuno-regulatory properties and they are a promising prospective therapy for multiple sclerosis and other autoimmune diseases. [...]
2019 - 10.3389/fimmu.2019.00157
Frontiers in immunology, Vol. 10 (February 2019) , art. 157
|
|